Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy Earns FDA Fast Track for Multiple Myeloma

Fineline Cube Jul 15, 2024

Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it...

Company Deals

Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit

Fineline Cube Jul 15, 2024

Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...

Company R&D

Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits

Fineline Cube Jul 15, 2024

Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on...

Company Drug

Simcere Pharmaceutical’s COVID-19 Therapy Xiannuoxin Earns Full Approval in China

Fineline Cube Jul 12, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...

Company Deals R&D

Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery

Fineline Cube Jul 12, 2024

Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in...

Company Drug

Jiangsu Hengrui’s Subsidiary Conducts First Surgical Dosing in Parkinson’s Gene Therapy Clinical Trial

Fineline Cube Jul 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Medical Device

Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities

Fineline Cube Jul 12, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent...

Company Drug

Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401

Fineline Cube Jul 12, 2024

Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first...

Company Deals

Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001

Fineline Cube Jul 12, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...

Company Drug

Eisai and Biogen’s Alzheimer’s Therapy Leqembi Receives Marketing Approval in Hong Kong

Fineline Cube Jul 12, 2024

Eisai Co., Ltd, a Japanese pharmaceutical company, along with its co-development partner Biogen Inc. (NASDAQ:...

Company Drug

Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity

Fineline Cube Jul 12, 2024

Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...

Company Drug

Novo Nordisk’s Awiqli Faces FDA Setback as BLA Draws Complete Response Letter

Fineline Cube Jul 12, 2024

Novo Nordisk A/S (NYSE: NVO) announced that the U.S. Food and Drug Administration issued a...

Company Drug

CSPC Pharmaceutical’s RSV mRNA Vaccine SYS6016 Receives Clinical Trial Approval from NMPA

Fineline Cube Jul 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for BL-M14D1 Clinical Trial in Solid Tumors

Fineline Cube Jul 12, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Beijing Sun-Novo Gets NMPA Green Light for STC008 Clinical Trial in Tumor Cachexia

Fineline Cube Jul 12, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has...

Company Medical Device

Haohai Biotech’s Sodium Hyaluronate Gel Receives NMPA Approval for Aesthetic Treatments

Fineline Cube Jul 12, 2024

Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366) has announced that it has...

Company

Danaher Corporation Launches Western Innovation Center in Chongqing

Fineline Cube Jul 12, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider based in the U.S.,...

Company Deals

Salus Biotech Partners with Xi’an Jiaotong University for Single-Cell Omics Innovation

Fineline Cube Jul 12, 2024

Salus Biotech, a Shenzhen-based biotechnology company, has entered into a strategic partnership with the Single-cell...

Company Drug

KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market

Fineline Cube Jul 12, 2024

Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...

Company Deals

Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others

Fineline Cube Jul 11, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s...

Posts pagination

1 … 278 279 280 … 613

Recent updates

  • Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
  • TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China
  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.